Ong, S.Y.; Tan Si Yun, M.; Abdul Halim, N.A.; Christopher, D.; Jen, W.Y.; Gallardo, C.; Tan Hwee Yim, A.; Woon, Y.K.; Ng, H.J.; Ooi, M.;
et al. Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Cancers 2022, 14, 3576.
https://doi.org/10.3390/cancers14153576
AMA Style
Ong SY, Tan Si Yun M, Abdul Halim NA, Christopher D, Jen WY, Gallardo C, Tan Hwee Yim A, Woon YK, Ng HJ, Ooi M,
et al. Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Cancers. 2022; 14(15):3576.
https://doi.org/10.3390/cancers14153576
Chicago/Turabian Style
Ong, Shin Yeu, Melinda Tan Si Yun, Nurul Aidah Abdul Halim, Dheepa Christopher, Wei Ying Jen, Christian Gallardo, Angeline Tan Hwee Yim, Yeow Kheong Woon, Heng Joo Ng, Melissa Ooi,
and et al. 2022. "Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine" Cancers 14, no. 15: 3576.
https://doi.org/10.3390/cancers14153576
APA Style
Ong, S. Y., Tan Si Yun, M., Abdul Halim, N. A., Christopher, D., Jen, W. Y., Gallardo, C., Tan Hwee Yim, A., Woon, Y. K., Ng, H. J., Ooi, M., & Wong, G. C.
(2022). Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Cancers, 14(15), 3576.
https://doi.org/10.3390/cancers14153576
